Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27924870 | 1.00 | CTSA (0.50) | CTSALMNAPOLBCNR2AVPR2 | |
| SCHEMBL10216855 | 0.87 | LMNA (0.48) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL10217086 | 0.86 | LMNA (0.47) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL10216766 | 0.86 | LMNA (0.47) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL19265317 | 0.85 | LMNA (0.46) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL10216923 | 0.85 | LMNA (0.46) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL17841293 | 0.85 | CTSA (0.50) | CTSACTSSCTSK | |
| SCHEMBL1157183 | 0.85 | CTSA (0.50) | CTSACTSSCTSK | |
| SCHEMBL12522403 | 0.84 | LMNA (0.45) | LMNAPOLBCNR2AVPR2AVPR1A | |
| SCHEMBL807809 | 0.84 | AVPR2 (0.44) | CTSALMNAPOLBCNR2AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | CTSA 58/4885LMNA 523/4885POLB 2129/4885 |
| US-20120238607-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | CTSA 266/4885LMNA 726/4885POLB 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.